581 related articles for article (PubMed ID: 28753016)
1. High-Throughput Metabolomics for Discovering Potential Metabolite Biomarkers and Metabolic Mechanism from the APPswe/PS1dE9 Transgenic Model of Alzheimer's Disease.
Yu J; Kong L; Zhang A; Han Y; Liu Z; Sun H; Liu L; Wang X
J Proteome Res; 2017 Sep; 16(9):3219-3228. PubMed ID: 28753016
[TBL] [Abstract][Full Text] [Related]
2. A Urinary Metabolomics Analysis Based on UPLC-MS and Effects of Moxibustion in APP/PS1 Mice.
He R; Liu J; Huang C; Liu J; Cui H; Zhao B
Curr Alzheimer Res; 2020; 17(8):753-765. PubMed ID: 33167836
[TBL] [Abstract][Full Text] [Related]
3. Region-specific metabolic alterations in the brain of the APP/PS1 transgenic mice of Alzheimer's disease.
González-Domínguez R; García-Barrera T; Vitorica J; Gómez-Ariza JL
Biochim Biophys Acta; 2014 Dec; 1842(12 Pt A):2395-402. PubMed ID: 25281826
[TBL] [Abstract][Full Text] [Related]
4. Urinary and faecal metabolic characteristics in APP/PS1 transgenic mouse model of Alzheimer's disease with and without cognitive decline.
Zheng Y; Xu Q; Jin Q; Du Y; Yan J; Gao H; Zheng H
Biochem Biophys Res Commun; 2022 May; 604():130-136. PubMed ID: 35303679
[TBL] [Abstract][Full Text] [Related]
5. Application of metabolomics based on direct mass spectrometry analysis for the elucidation of altered metabolic pathways in serum from the APP/PS1 transgenic model of Alzheimer's disease.
González-Domínguez R; García-Barrera T; Vitorica J; Gómez-Ariza JL
J Pharm Biomed Anal; 2015 Mar; 107():378-85. PubMed ID: 25656489
[TBL] [Abstract][Full Text] [Related]
6. Metabolomics reveals significant impairments in the immune system of the APP/PS1 transgenic mice of Alzheimer's disease.
González-Domínguez R; García-Barrera T; Vitorica J; Gómez-Ariza JL
Electrophoresis; 2015 Feb; 36(4):577-87. PubMed ID: 25393935
[TBL] [Abstract][Full Text] [Related]
7. Urinary metabolomics study the mechanism of Taohong Siwu Decoction intervention in acute blood stasis model rats based on liquid chromatography coupled to quadrupole time-of-flight mass spectrometry.
Zhang X; Li P; Hua Y; Ji P; Yao W; Ma Q; Yuan Z; Wen Y; Yang C; Wei Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Feb; 1074-1075():51-60. PubMed ID: 29331744
[TBL] [Abstract][Full Text] [Related]
8. Urine Metabonomics Reveals Early Biomarkers in Diabetic Cognitive Dysfunction.
Song L; Zhuang P; Lin M; Kang M; Liu H; Zhang Y; Yang Z; Chen Y; Zhang Y
J Proteome Res; 2017 Sep; 16(9):3180-3189. PubMed ID: 28722418
[TBL] [Abstract][Full Text] [Related]
9. Urinary Metabolomics Reveals Alterations of Aromatic Amino Acid Metabolism of Alzheimer's Disease in the Transgenic CRND8 Mice.
Tang Z; Liu L; Li Y; Dong J; Li M; Huang J; Lin S; Cai Z
Curr Alzheimer Res; 2016; 13(7):764-76. PubMed ID: 26825095
[TBL] [Abstract][Full Text] [Related]
10. Deciphering metabolic abnormalities associated with Alzheimer's disease in the APP/PS1 mouse model using integrated metabolomic approaches.
González-Domínguez R; García-Barrera T; Vitorica J; Gómez-Ariza JL
Biochimie; 2015 Mar; 110():119-128. PubMed ID: 25597416
[TBL] [Abstract][Full Text] [Related]
11. High-throughput metabolomics and ingenuity pathway approach reveals the pharmacological effect and targets of Ginsenoside Rg1 in Alzheimer's disease mice.
Li G; Zhang N; Geng F; Liu G; Liu B; Lei X; Li G; Chen X
Sci Rep; 2019 May; 9(1):7040. PubMed ID: 31065079
[TBL] [Abstract][Full Text] [Related]
12. Metabolomics approach to explore the effects of Kai-Xin-San on Alzheimer's disease using UPLC/ESI-Q-TOF mass spectrometry.
Chu H; Zhang A; Han Y; Lu S; Kong L; Han J; Liu Z; Sun H; Wang X
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Mar; 1015-1016():50-61. PubMed ID: 26896572
[TBL] [Abstract][Full Text] [Related]
13. Widely targeted metabolomics of Alzheimer's disease postmortem cerebrospinal fluid based on 9-fluorenylmethyl chloroformate derivatized ultra-high performance liquid chromatography tandem mass spectrometry.
Muguruma Y; Tsutsui H; Noda T; Akatsu H; Inoue K
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Aug; 1091():53-66. PubMed ID: 29852382
[TBL] [Abstract][Full Text] [Related]
14. Metabolomics approach based on utra-performance liquid chromatography coupled to mass spectrometry with chemometrics methods for high-throughput analysis of metabolite biomarkers to explore the abnormal metabolic pathways associated with myocardial dysfunction.
Zhao LK; Zhao YB; Yu PC; Zhang PX
Biomed Chromatogr; 2020 Aug; 34(8):e4847. PubMed ID: 32285481
[TBL] [Abstract][Full Text] [Related]
15. A UPLC-TOF/MS-based metabolomics study of rattan stems of Schisandra chinensis effects on Alzheimer's disease rats model.
Yang BY; Tan JY; Liu Y; Liu B; Jin S; Guo HW; Kuang HX
Biomed Chromatogr; 2018 Feb; 32(2):. PubMed ID: 28664556
[TBL] [Abstract][Full Text] [Related]
16. Metabolomic investigation of systemic manifestations associated with Alzheimer's disease in the APP/PS1 transgenic mouse model.
González-Domínguez R; García-Barrera T; Vitorica J; Gómez-Ariza JL
Mol Biosyst; 2015 Sep; 11(9):2429-40. PubMed ID: 26131452
[TBL] [Abstract][Full Text] [Related]
17. Early alterations in energy metabolism in the hippocampus of APPswe/PS1dE9 mouse model of Alzheimer's disease.
Pedrós I; Petrov D; Allgaier M; Sureda F; Barroso E; Beas-Zarate C; Auladell C; Pallàs M; Vázquez-Carrera M; Casadesús G; Folch J; Camins A
Biochim Biophys Acta; 2014 Sep; 1842(9):1556-66. PubMed ID: 24887203
[TBL] [Abstract][Full Text] [Related]
18. Proteomic analysis of serum proteins in triple transgenic Alzheimer's disease mice: implications for identifying biomarkers for use to screen potential candidate therapeutic drugs for early Alzheimer's disease.
Sui X; Ren X; Huang P; Li S; Ma Q; Ying M; Ni J; Liu J; Yang X
J Alzheimers Dis; 2014; 40(3):575-86. PubMed ID: 24496070
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic and urinary metabolomics studies on the mechanism of Schisandra polysaccharide in the treatment of Alzheimer's disease.
Liu Y; Liu Z; Wei M; Hu M; Yue K; Bi R; Zhai S; Pi Z; Song F; Liu Z
Food Funct; 2019 Jan; 10(1):432-447. PubMed ID: 30623955
[TBL] [Abstract][Full Text] [Related]
20. Metabolomic screening of regional brain alterations in the APP/PS1 transgenic model of Alzheimer's disease by direct infusion mass spectrometry.
González-Domínguez R; García-Barrera T; Vitorica J; Gómez-Ariza JL
J Pharm Biomed Anal; 2015 Jan; 102():425-35. PubMed ID: 25459942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
